Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | CRHBP | P24387 | 1/20 | 0.35 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | AHR | P35869 | 4/20 | 0.34 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3061282 | 0.87 | ALDH1A1 (0.43) | ALDH1A1CYP3A4HPGDCRHBPCRHR2 | |
| SCHEMBL2192678 | 0.82 | HSD17B10 (0.42) | ALDH1A1CYP3A4HPGDHSD17B10 | |
| SCHEMBL829628 | 0.78 | TSHR (0.40) | CYP3A4 | |
| SCHEMBL1578248 | 0.77 | AHR (0.37) | ALDH1A1CYP3A4HSD17B10AHRCYP1B1 | |
| SCHEMBL14739391 | 0.75 | — | — | |
| SCHEMBL9847915 | 0.74 | MEN1 (0.35) | ALDH1A1CYP3A4HPGD | |
| SCHEMBL18662116 | 0.73 | ALDH1A1 (0.30) | ALDH1A1 | |
| SCHEMBL8794846 | 0.70 | KDM4E (0.35) | ALDH1A1HSD17B10 | |
| SCHEMBL8013446 | 0.70 | HSD17B10 (0.50) | ALDH1A1CYP3A4HPGDCRHBPCRHR2 | |
| SCHEMBL9672417 | 0.69 | MAPT (0.38) | ALDH1A1HPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11919921-B2 | Galactoside inhibitor of galectins | GALECTO BIOTECH AB (DK) | 2024-03-05 | — | — | US | disclosed |
| US-20220289783-A1 | NOVEL GALACTOSIDE INHIBITOR OF GALECTINS | GALECTO BIOTECH AB (DK) | 2022-09-15 | — | — | US | disclosed |
| US-11377464-B2 | Galactoside inhibitor of galectins | GALECTO BIOTECH AB (DK) | 2022-07-05 | — | — | US | disclosed |
| CN-113621005-A | alpha-D-galactoside inhibitors of galectins | 格莱克特生物技术公司 | 2021-11-09 | — | — | CN | disclosed |
| CN-107406478-B | alpha-D-galactoside inhibitors of galectins | 格莱克特生物技术公司 | 2021-07-27 | — | — | CN | disclosed |
| EP-3828191-A2 | NOVEL GALACTOSIDE INHIBITOR OF GALECTINS | Galecto Biotech AB (DK) | 2021-06-02 | — | — | EP | disclosed |
| EP-3250581-B1 | ALPHA-D-GALACTOSIDE INHIBITORS OF GALECTINS | GALECTO BIOTECH AB (DK) | 2021-01-20 | — | — | EP | disclosed |
| US-20200407391-A1 | NOVEL GALACTOSIDE INHIBITOR OF GALECTINS | GALECTO BIOTECH AB (DK) | 2020-12-31 | — | — | US | disclosed |
| US-10774102-B2 | Galactoside inhibitor of galectins | GALECTO BIOTECH AB (DK) | 2020-09-15 | — | — | US | disclosed |
| US-20170349619-A1 | ALPHA-D-GALACTOSIDE INHIBITORS OF GALECTINS | GALECTO BIOTECH AB (DK) | 2017-12-07 | — | — | US | disclosed |
| EP-3250581-A1 | ALPHA-D-GALACTOSIDE INHIBITORS OF GALECTINS | Galecto Biotech AB (DK) | 2017-12-06 | — | — | EP | disclosed |
| WO-2016120403-A1 | ALPHA-D-GALACTOSIDE INHIBITORS OF GALECTINS | GALECTO BIOTECH AB (DK) | 2016-08-04 | — | — | WO | disclosed |
| US-20070072859-A1 | Pharmaceutical compounds | ELI LILLY AND COMPANY (US) | 2007-03-29 | — | — | US | disclosed |
| EP-1725518-A1 | PHARMACEUTICAL COMPOUNDS | ELI LILLY AND COMPANY (US) | 2006-11-29 | — | — | EP | disclosed |
| WO-2005092835-A1 | PHARMACEUTICAL COMPOUNDS | ELI LILLY AND COMPANY (US) | 2005-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200407391-A1 | NOVEL GALACTOSIDE INHIBITOR OF GALECTINS | LGALS1, LGALS3, LGALS2 | ALDH1A1 1785/4885CYP3A4 4312/4885HPGD 3116/4885 |
| US-11377464-B2 | Galactoside inhibitor of galectins | LGALS3, LGALS1, LGALS2 | ALDH1A1 1974/4885CYP3A4 4163/4885HPGD 2838/4885 |
| US-11919921-B2 | Galactoside inhibitor of galectins | LGALS3, LGALS1, LGALS2 | ALDH1A1 1974/4885CYP3A4 4163/4885HPGD 2838/4885 |
| US-20070072859-A1 | Pharmaceutical compounds | ADRB3, HTR3C, SLC6A2 | ALDH1A1 1174/4885CYP3A4 273/4885HPGD 2147/4885 |
| US-20220289783-A1 | NOVEL GALACTOSIDE INHIBITOR OF GALECTINS | LGALS1, LGALS3, LGALS2 | ALDH1A1 1785/4885CYP3A4 4312/4885HPGD 3116/4885 |
| US-20170349619-A1 | ALPHA-D-GALACTOSIDE INHIBITORS OF GALECTINS | LGALS3, LGALS1, LGALS2 | ALDH1A1 1252/4885CYP3A4 4028/4885HPGD 1958/4885 |
| US-10774102-B2 | Galactoside inhibitor of galectins | LGALS3, LGALS1, LGALS2 | ALDH1A1 1974/4885CYP3A4 4163/4885HPGD 2838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.